Invasive pneumococcal disease in patients with an underlying pulmonary disorder

Clinical Microbiology and Infection

Volumn 19, Issue 12, 2013, Pages 1148-1154

  Inghammar, M ^a   Engstrom G ^b   Kahlmeter, G ^c   Ljungberg, B ^a   Lofdahl C G ^a   Egesten, A ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c CENTRAL HOSPITAL   (Sweden)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Epidemiology; Pneumococcal infections; Pulmonary fibrosis; Sarcoidosis

Indexed keywords

ADULT; AGED; ALLERGIC PNEUMONITIS; ARTICLE; ASTHMA; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FEMALE; HUMAN; INFECTION RISK; LUNG DISEASE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PNEUMOCOCCAL INFECTION; PNEUMOCONIOSIS; PRIORITY JOURNAL; SARCOIDOSIS; SOCIAL STATUS;

ASTHMA; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; EPIDEMIOLOGY; PNEUMOCOCCAL INFECTIONS; PULMONARY FIBROSIS; SARCOIDOSIS;

ADULT; AGED; AGED, 80 AND OVER; ASTHMA; CASE-CONTROL STUDIES; CHRONIC DISEASE; COMORBIDITY; DATABASES, FACTUAL; HUMANS; LOGISTIC MODELS; LUNG DISEASES; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SWEDEN; YOUNG ADULT;

EID: 84888074751     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12182     Document Type: Article

References (29)

1. Epidemiologisk årsrapport. http://www.Smi.Se/upload/publikationer/epidemiologisk-%c3%a5rsrapport-2010-2011-1-5.Pdf. In: Control. SIfCD, ed. 2011-1-5 edn 2010.
2. Talbot TR, Hartert TV, Mitchel E et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med 2005; 352: 2082-2090.
3. Klemets P, Lyytikainen O, Ruutu P, Ollgren J, Nuorti JP. Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect Dis 2008; 8: 96.
4. Kyaw MH, Rose CE Jr, Fry AM et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005; 192: 377-386.
5. Kalin M, Ortqvist A, Almela M et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000; 182: 840-847.
6. Laurichesse H, Romaszko JP, Nguyen LT et al. Clinical characteristics and outcome of patients with invasive pneumococcal disease, Puy-de-Dome, France, 1994-1998. Eur J Clin Microbiol Infect Dis 2001; 20: 299-308.
7. Ludvigsson JF, Andersson E, Ekbom A et al. External review and validation of the Swedish National Inpatient Register. BMC Public Health 2011; 11: 450.
8. Inghammar M, Engstrom G, Lofdahl CG, Egesten A. Validation of a COPD diagnosis from the Swedish Inpatient Registry. Scand J Public Health 2012; 8: 773-776.
9. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-2365.
10. Berenson CS, Wrona CT, Grove LJ et al. Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 174: 31-40.
11. Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res 2005; 6: 68.
12. Nuorti JP, Butler JC, Farley MM et al. Cigarette smoking and invasive pneumococcal disease. Active bacterial core surveillance team. N Engl J Med 2000; 342: 681-689.
13. Statens folkhälsoinstitut (2011f). Nationella folkhälsoenkäten: Levnadsvanor: Tobaksvanor. Hämtad 2011-09-26, från http://www.Fhi.Se/statistik-uppfoljning/nationella-folkhalsoenkaten/levnadsvanor/tobaksvanor/.
14. Lofdahl CG, Tilling B, Ekstrom T, Jorgensen L, Johansson G, Larsson K. COPD health care in Sweden - a study in primary and secondary care. Respir Med 2010; 104: 404-411.
15. Lindberg A, Larsson LG, Muellerova H, Ronmark E, Lundback B. Up-to-date on mortality in COPD - report from the Olin COPD study. BMC Pulm Med 2012; 12: 1.
16. Raghu G, Collard HR, Egan JJ et al. An official ats/ers/jrs/alat statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
17. Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and other Granulomatous Sisorders (WASOG) adopted by the ATS board of directors and by the ERS executive committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736-755.
18. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 954-963.
19. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009; 169: 219-229.
20. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 2407-2416.
21. Sin DD, Tashkin D, Zhang X et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712-719.
22. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011; 37: 356-363.
23. Richter AG, Stockley RA, Harper L, Thickett DR. Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis. Thorax 2009; 64: 692-697.
24. Park JH, Kim DS, Park IN et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175: 705-711.
25. Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990; 88: 396-404.
26. Berg S, Trollfors B, Persson E et al. Serotypes of Streptococcus pneumoniae isolated from blood and cerebrospinal fluid related to vaccine serotypes and to clinical characteristics. Scand J Infect Dis 2006; 38: 427-432.
27. Spindler C, Hedlund J, Jasir A, Normark BH, Ortqvist A. Effects of a large-scale introduction of the pneumococcal polysaccharide vaccine among elderly persons in Stockholm, Sweden. Vaccine 2008; 26: 5541-5546.
28. Mirzanejad Y, Roman S, Talbot J, Nicolle L. Pneumococcal bacteremia in two tertiary care hospitals in Winnipeg, Canada. Pneumococcal bacteremia study group. Chest 1996; 109: 173-178.
29. Jansen AG, Rodenburg GD, van der Ende A et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009; 49: e23-e29.